News

Filter

Current filters:

BiosimilarsRoche

1 to 9 of 13 results

Roche likely to lose another state contract in Russia

Roche likely to lose another state contract in Russia

23-02-2015

Swiss pharma giant Roche will probably lose one of its major contracts in Russia for the next several…

AvastinBiocadBiosimilarsBiotechnologyMarkets & MarketingOncologyRocheRussia

Pfenex soars on Lucentis biosimilar deal with Hospira

Pfenex soars on Lucentis biosimilar deal with Hospira

10-02-2015

Shares of US clinical-stage biotech firm Pfenex leapt 28% to $8.85 in morning trading, after the company…

BiosimilarsBiotechnologyGenentechGlobalHospiraLicensingLucentisNovartisOphthalmicsPF582PfenexResearchRoche

Increased scrutiny by EU5 health authorities will encourage off-label use of Avastin for wet-AMD

06-11-2014

Cost-constrained health authorities in the EU5 (France, Germany, Italy, Spain, and the UK) are increasingly…

AvastinBiosimilarsBiotechnologyEuropeFinancialLucentisMarkets & MarketingNovartisOphthalmicsRoche

Russia’s Generium to establish MabThera analogue production

16-10-2014

Generium Group of Companies, one of Russia’s largest producers of innovative drugs, has commissioned…

BiosimilarsBiotechnologyGeneriumMabTheraOncologyProductionRocheRussia

Big Pharma's control over the Russian state drug procurement tenders market slipping away, says Biocad

16-10-2014

Russian pharmaceutical companies are actively squeezing out foreign therapeutic manufacturers from the…

AcellBiaBiocadBiosimilarsBiotechnologyMabTheraMarkets & MarketingOncologyRituxanRocheRussia

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

10-06-2014

Certain targeted therapies enjoy extensive but incomplete coverage in Brazil and Mexico through complex…

BiosimilarsBrazilJohnson & JohnsonMabTheraMexicoOncologyPharmaceuticalPricingRocheVelcade

Biocad’s AcellBia is first MAb biosimilar approved by Russia’s Ministry of Health

15-05-2014

A biosimilar of Swiss drug major Roche’s MabThera (rituximab), to be marketed under the trade name…

AcellBiaBiocadBiosimilarsGenericsMabTheraOncologyRegulationRocheRussia

Roche may lose $240 million contract in Russia to Biocad biosimilar

Roche may lose $240 million contract in Russia to Biocad biosimilar

07-05-2014

Swiss drug major Roche may lose an important $240 million contract in Russia for the supply of its anti-cancer…

AcellBiaBiocadBiosimilarsBiotechnologyMabTheraMarkets & MarketingOncologyRegulationrituximabRoche

1 to 9 of 13 results

COMPANY SPOTLIGHT

Menarini

Back to top